Anti-COVID-19 drug 2-deoxy-D-glucose (2-DG) has been developed by INMAS, a lab of Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy`s Laboratories (DRL), Hyderabad
A drug developed by the Defence Research and Development Organisation (DRDO) and approved by the Drug Controller General of India (DCGI) for “emergency use” in those with moderate to severe COVID may soon make its way to hospitals for treating moderate and severely ill patients, but independent experts say that from the information so far available, the drug's utility in COVID care has not been established.He pointed out that in phase 3, the freedom from oxygen dependence has been seen in 42 per cent of the patients by the third day as compared to 31 per cent in standard care.
A drug developed by the Defence Research and Development Organisation (DRDO) and approved by the Drug Controller General of India (DCGI) for “emergency use” in those with moderate to severe COVID may soon make its way to hospitals for treating moderate and severely ill patients, but independent experts say that from the information so far available, the drug's utility in COVID care has not been established.He pointed out that in phase 3, the freedom from oxygen dependence has been seen in 42 per cent of the patients by the third day as compared to 31 per cent in standard care.
